Alvotech
ALVOHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 8, 2026
Scan Results
Daily timeframeAlvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. Valued at $1.90B, ALVO is a small-cap name in its sector. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Market Cap
$1.90B
Beta
0.22
P/E (TTM)
—
P/E (Fwd)
23.30
EPS (TTM)
$-0.62
EPS (Fwd)
$0.23
ROE
—
ROA
2.2%
Cash
$142.8M
Total Debt
$1.45B
Free CF
-$123.1M
52W Change
-34.4%
Annual Financials
Cash vs Debt
Where ALVO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ALVO finished 39.43% above its 150-day moving average ($3.83) and 28.67% above its 200-day moving average ($4.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALVO overbought or oversold?
At the September 3, 2026 close, ALVO's RSI(14) was 75.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Alvotech carries $1.45B in total debt against $142.8M in cash reserves — debt is roughly 10.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$123.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROA of 2.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $83.0M (2022) to $586.3M (2025), reflecting a 606% increase over the period.
With a beta below 0.7, Alvotech typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Alvotech and its sector.